Science 37, a Los Angeles, CA-based provider of decentralized clinical trials, closed a $40m funding round.
The round was led by existing investors Lux Capital, Redmile Group, and PPD, Inc. (Nasdaq: PPD), joined by existing investors Novartis, Amgen, Sanofi Ventures, GV, and Glynn Capital. New investors included LifeSci Ventures and Mubadala Ventures.
The company will use the new capital to support its growth, expand its technology platform, and accelerate its global expansion efforts—further strengthening its ability to help sponsors execute decentralized trials and enable patients to participate in trials from anywhere, without traveling to a traditional clinical site.
Led by David Coman, CEO, Science 37 provides decentralized, interventional trials, using an expansive network of telemedicine investigators and home-health nurses, who are supported by an integrated, decentralized clinical trial platform.